Injeq Oyj is a Finnish MedTech company, that offers unique smart needles for demanding patient injections, such as lumbar punctures. Injeq uses patented technology, and currently, there are no competing products on the market.
“Our technology has the potential to transform the way that lumbar punctures are conducted for adults, newborns and people with difficult anatomy. Furthermore, Injeq intends to bring equal, affordable healthcare to all including patients in developing regions of the world”, says Timo Hänninen, Injeq’s CEO.
Key investment highlights:
☆ Complete and licensed product – Injeq is a Finnish medical technology company currently in the commercial expansion phase having received a CE certification for its first product, the IQ-Tip®, in late 2021.
☆ Solution to a predominant problem – The IQ-Tip® is a new, safe, and more efficient alternative to the current lumbar puncture methods bringing real added value to doctors and patients all over the world.
☆ Solid growth strategy with first steps already implemented – Injeq is currently scaling in the European market after which it aims to expand its distributor network and operations to new markets. Injeq currently has distributor agreements in 14 European countries and additionally in Kuwait and Taiwan.
☆ Scaling business model currently in ramp-up phase – Injeq’s technology is scalable and can also be expanded to cover other application areas than lumbar punctures. Injeq has begun the first deliveries of the IQ-Tip®.
☆ Capable and highly experienced management – Injeq’s highly capable and experienced management and board of directors are committed to developing the Company.